Skip to main content

Advertisement

SpringerLink
Log in

PSORIATIC ARTHRITIS

Guselkumab effective through 2 years in PsA trial

  • In Brief
  • Published:

From Nature Reviews Rheumatology

View current issue Sign up to alerts

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

Original article

  • McInnes, I. B. et al. Long-term efficacy and safety of guselkumab, a monoclonal antibody specific to the p19 subunit of interleukin-23, through 2 years: results from a phase 3, randomized, double-blind, placebo-controlled study conducted in biologic-naive patients with active psoriatic arthritis. Arthritis Rheumatol. https://doi.org/10.1002/art.42010 (2021)

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Nature Reviews Rheumatology http://www.nature.com/nrrheum/

    Sarah Onuora

Authors
  1. Sarah Onuora
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sarah Onuora.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Onuora, S. Guselkumab effective through 2 years in PsA trial. Nat Rev Rheumatol 18, 4 (2022). https://doi.org/10.1038/s41584-021-00733-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41584-021-00733-9

  • Springer Nature Limited

Search

Navigation